Evidence map›Paper›PMID 30420872›Full record

ReviewPPAR research2018

Signaling Mechanisms of Selective PPAR

Manoj Govindarajulu, Priyanka D Pinky, Jenna Bloemer, Nila Ghanei, Vishnu Suppiramaniam, Rajesh Amin

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in PPAR research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 68 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?International journal of molecular sciences · 2024
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Manoj GovindarajuluDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.
Priyanka D PinkyDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.ORCID 0000-0002-0650-4280
Jenna BloemerDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.ORCID 0000-0002-1090-0286
Nila GhaneiDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.
Vishnu SuppiramaniamDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.ORCID 0000-0003-0850-3940
Rajesh AminDepartment of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.ORCID 0000-0001-8741-0018
Auburn University · US

Funding

Novel PPAR-gamma agonist selectively activate the ligand binding domain of PPAR-gamma and improve pathology and memory deficits in a 3xTg-Ad mouse model.R15AG048643 · NIA · AUBURN UNIVERSITY AT AUBURN · PI AMIN, RAJESH H, SUPPIRAMANIAM, VISHNU D · 2015 to 2015
$362k
NIA NIH HHS R15 AG048643
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by abnormal protein accumulation, synaptic dysfunction, and cognitive impairment. The continuous increase in the incidence of AD with the aged population and mortality rate indicates the urgent need for establishing novel molecular targets for therapeutic potential. Peroxisome proliferator-activated receptor gamma (PPAR

Identifiers

PMID30420872
PMCPMC6215547
OpenAlexW2895949704

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.